NasdaqGS:ONCBiotechs
The Bull Case For BeOne Medicines (ONC) Could Change Following Strong Sonrotoclax B‑Cell Cancer Data - Learn Why
In December 2025, BeOne Medicines reported new clinical data at the ASH meeting showing its investigational BCL2 inhibitor sonrotoclax delivered meaningful benefit in difficult-to-treat B-cell malignancies, including relapsed or refractory mantle cell lymphoma with over half of patients responding in a Phase 1/2 study under U.S. FDA Priority Review for potential accelerated approval.
The findings, including rapid and sustained undetectable minimal residual disease in treatment‑naive chronic...